Welcome

By clicking "Continue to the HCP site," you are certifying that you are a licensed US healthcare professional (HCP) and a US resident.

If you are a patient who wants to learn more about VASCEPA, click vascepa.com

With VASCEPA, early action can translate into significant CV risk* reduction1-3

For adults on maximally tolerated statins with TG ≥150 mg/dL and established CVD or diabetes and ≥2 CVD risk factors

Adding VASCEPA significantly reduced CV events, such as MI or stroke, beyond reductions seen with statins + standard-of-care therapies1-4†

See Graph

25% RRR; NNT=21

ARR=4.8%; P=0.00000001

Composite first occurrence of
5-point MACE (primary endpoint)

Composite first occurrence of 5-point MACE (primary endpoint)

close

Composite first occurrence of 5-point MACE (primary endpoint)

Composite first occurrence of 5-point MACE (primary endpoint)Composite first occurrence of 5-point MACE (primary endpoint)Composite first occurrence of 5-point MACE (primary endpoint)
Composite first occurrence of 5-point MACE (primary endpoint)
Composite first occurrence of 5-point MACE (primary endpoint)Composite first occurrence of 5-point MACE (primary endpoint)

At Year 5 since randomization, 1430 patients remained in the VASCEPA arm vs 1358 patients in the placebo arm.

ARR=absolute risk reduction; MACE=major adverse cardiovascular events; NNT=number needed to treat; RRR=relative risk reduction.

  • 5-point MACE primary composite endpoint was defined as Nonfatal MI, Nonfatal Stroke, CV Death, Coronary Revascularization, or Unstable Angina Requiring Hospitalization
  • Patients in the Placebo + Statin arm had a cumulative 28.3% event rate, which is consistent for this high-risk population3

A randomized, double-blind, placebo-controlled trial for adults with eCVD or with diabetes and other risk factors, receiving statin therapy, and with modestly elevated TG (median baseline 216 mg/dL) and well-controlled LDL-C (median baseline 75 mg/dL). 8179 patients (VASCEPA 4 g/d [n=4089]; placebo [n=4090]) were followed for a median of 4.9 years.

Patients in the VASCEPA CV Outcomes Trial (REDUCE-IT) received standard-of-care medications including statins (100%), antihypertensives (95%), antiplatelet medication (79%), ACE inhibitors (52%), ARBs (27%), and beta blockers (71%).

See the data in the NEJM publication

Significantly reduced the risk of MI, stroke, or CV death1-3

Significantly reduced the risk of MI, stroke, or CV deathSignificantly reduced the risk of MI, stroke, or CV death

NNT=number needed to treat; RRR=relative risk reduction.

At Year 5 since randomization, 1562 patients remained in the VASCEPA arm vs 1487 patients in the placebo arm.

  • 3-point MACE key secondary composite endpoint was defined as Nonfatal MI, Nonfatal Stroke, or CV Death
  • 35% reduction in urgent or emergent Coronary Revascularization; P<0.001
  • 32% reduction in Unstable Angina Requiring Hospitalization; P=0.002
  • 71% of studied patients had a prior CV event

Get patients started on VASCEPA

Learn how

Robust CV risk reduction irrespective of achieved TG levels1,2

Primary endpoint by achieved triglyceride level at 1 year

Primary endpoint by achieved triglyceride level at 1 year
Primary endpoint by achieved triglyceride level at 1 year
Primary endpoint by achieved triglyceride level at 1 year
Primary endpoint by achieved triglyceride level at 1 year

Reproduced from The New England Journal of Medicine, Vol 380, Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia, pp 11-22. Copyright 2019, with permission from Massachusetts Medical Society

At Year 5 since randomization, 571 patients with TG <150 mg/dL and 803 patients with TG ≥150 mg/dL remained in the VASCEPA arm vs 1358 patients in the placebo arm.

  • Median percent change in TG for VASCEPA 4 g/d compared to placebo was -19.7%. Median percent change in LDL-C for VASCEPA 4 g/d compared to placebo was -6.6%
  • VASCEPA has multiple effects that extend beyond TG lowering, including increased EPA lipid composition from carotid plaque specimens. Direct clinical meaning of the findings is not clear

Indicate “Dispense as written (DAW-1)” or “Brand medically necessary” to ensure patients are getting the CV benefits of VASCEPA1

This site uses cookies to give you the best possible experience. By browsing our website, you agree to our use of cookies. If you require further information and/or do not wish to have cookies placed when using the site, visit the Privacy Policy page.

IMPORTANT SAFETY INFORMATION

• VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components

• VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter

• It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur

INDICATIONS AND LIMITATIONS OF USE

• VASCEPA® (icosapent ethyl) is indicated as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥150 mg/dL) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease

• VASCEPA is indicated as an adjunct to diet to reduce TG levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia

The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.

• VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a double-blind, placebo-controlled trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel or warfarin

• Common adverse reactions in the cardiovascular outcomes trial (incidence ≥3% and ≥1% more frequent than placebo): musculoskeletal pain (4% vs 3%), peripheral edema (7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%) and atrial fibrillation (5% vs 4%)

• Common adverse reactions in the hypertriglyceridemia trials (incidence ≥1% more frequent than placebo): arthralgia (2% vs 1%) and oropharyngeal pain (1% vs 0.3%)

• Adverse Events, Product Complaints, or Special Situations may be reported by contacting AmarinConnect at 1-855-VASCEPA, emailing [email protected], or calling the FDA at 1-800-FDA-1088

• Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents should be monitored for bleeding

Please see full Prescribing Information for more information on VASCEPA.

Visual representations are for illustrative purposes only. The capsule shown is not an identical representation of the product.

ACE=angiotensin-converting enzyme; ARBs=angiotensin II receptor blockers; CI=confidence interval; CV=cardiovascular; CVD=cardiovascular disease; eCVD=established cardiovascular disease; EPA=eicosapentaenoic acid; LDL-C=low-density lipoprotein cholesterol; MI=myocardial infarction; TG=triglyceride.

*Cardiovascular risk associated with events including myocardial infarction, stroke, CV death, coronary revascularization, and unstable angina requiring hospitalization.

†Patients in the VASCEPA CV Outcomes Trial (REDUCE-IT) received standard-of-care medications including statins (100%), antihypertensives (95%), antiplatelet medication (79%), ACE inhibitors (52%), ARBs (27%), and beta blockers (71%).

‡First occurrence of event.

References: 1. VASCEPA [package insert]. Bridgewater, NJ: Amarin Pharma, Inc.; 2021. 2. Bhatt DL, Steg PG, Miller M, et al; for the REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22. 3. Bhatt DL, Steg PG, Miller M, et al. Reduction of cardiovascular events with icosapent ethyl–intervention trial. Presented at: American Heart Association Scientific Sessions; November 10-12, 2018; Chicago, IL. 4. Bhatt DL, Steg PG, Miller M, et al; on behalf of the REDUCE-IT Investigators. Effects of icosapent ethyl on total ischemic events: from REDUCE-IT. J Am Coll Cardiol. 2019;73(22):2791-2802.

CO and VT prescribers only: Click here for statutory price disclosure information.

VASCEPA, Amarin, REDUCE-IT, and Vascepa/Amarin logos are registered trademarks of Amarin Pharmaceuticals Ireland Limited.

All other trademarks are the property of their respective companies.

© 2023 Amarin Pharmaceuticals Ireland Limited.  All rights reserved.  VAS-03038v14  02/23

This website, Vascepa.com, Vascepasavings.com, Truetoyourheart.com, and the corporation's website, amarincorp.com, are the only company-sanctioned websites pertaining to the Amarin group of companies or its product, Vascepa® (icosapent ethyl) capsules. The Amarin group of companies is not responsible for false or misleading materials contained on other non–Amarin-controlled websites or other social media sites.